Hugh O’Dowd
Director & Chairman
Hugh is an independent Non-executive Director and Chairman of ONK Therapeutics Board. He has significant life sciences industry experience in building organizations and the commercialization of oncology therapeutics.
Anthony Killarney
Founder & Director
Anthony Killarney is a Founder of ONK Therapeutics and now serves as a Director, having been Chairman of the Board until January 2021.
Eunan Maguire
Director
Eunan Maguire is founding director and experienced biopharmaceutical executive. Most recently he co-founded Adapt Pharma, a leader in opioid overdose treatment, where he served as its Chief Operating Officer until its sale to Emergent BioSolutions.
Isaac Manke, PhD
Director
Isaac Manke is an experienced life sciences venture capitalist and represents Acorn BioVentures on the board. He joined Acorn BioVentures as a General Partner in 2020. Previously, he was a General Partner at New Leaf Venture Partners.
Chris Nowers
CEO & Director
Chris Nowers is a senior global biopharma executive with significant experience in the areas of cell therapy and immuno-oncology. He joined ONK Therapeutics as CEO in October 2020.
Michael O’Dwyer, MD
Founder, CSO & Director
Michael O’Dwyer is an experienced Clinician Scientist with a strong track record in clinical and translational research in blood cancers and has been involved in the clinical drug development of many ground-breaking treatments. He is a Founder of ONK Therapeutics and has been the company’s CSO since its inception in 2015.
Raymond Kelleher, MD, PhD
Director
Raymond (‘Ray’) Kelleher is an accomplished clinician-scientist, company founder, and investor. He represents Cormorant Asset Management on the board.
Allan Reine, MD
Director
Allan Reine is an experienced biotechnology chief financial officer and investor who has been active in the industry since 2001.
George Schlich
Patent Attorney & Director
George Schlich is a UK and European Patent Attorney, a founding director of ONK Therapeutics and has been responsible from the start for the IP portfolio.
